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1. Introduction
It is only in recent years that the attention was drawn on the important role of the kidney in
glucose homeostasis. Nevertheless, along with the liver, the kidney has an important role in
ensuring the energy needs during fasting periods. This organ has a vital role in absorbing the
entire quantity of the filtered glucose [1]. Having a glomerular filtration rate of 180 liters per
day, it filters approximately 180 grams of glucose per day, bringing its contribution in
maintaining normal fasting plasma glucose (FPG) levels [2]. The reabsorption of glucose is
ensured by the sodium-glucose cotransporter (SGLT) 2, responsible for the reabsorption of
90% of glucose, and SGLT1, that reabsorbs the remaining glucose [3].
Despite the large amount of data regarding the implication of the kidneys in glucose homeo‐
stasis, this organ is often overlooked as a key player in glucose metabolism. But the awareness
of the renal mechanisms of glucose control is likely to increase due to the development of new
types of glucose-lowering drugs that target this metabolic pathway [4].
2. Short history
2.1. Early non-human studies
The first researchers in this field, Bergman and Drury brought the first clues about the
involvement of the kidney in glucose homeostasis in 1938 [5]. They used the glucose clamp
technique in order to maintain euglycemia in two groups of rabbits – one functionally
hepatectomized and another one functionally hepatectomized and nephrectomized. In the
group of hepatectomized and nephrectomized rabbits, the amount of glucose requested in
order to maintain euglycemia was very high compared to the one required by the other group
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[6] (Figure 1). These data led to the conclusion that the kidneys are an important source of
plasma glucose [6].
Figure 1. Effect of nephrectomy on glucose needs for maintaining euglycemia in hepatectomized rabbits (Adapted
from [6])
A few years later, the study was reproduced by Reinecke in rats. He also determined the
arteriorenal venous glucose concentrations in the hepatectomized rats. He found that the
glucose levels in renal vein exceeded the arterial levels when the animals became hypogly‐
cemic  proving  that,  under  these  conditions,  the  kidneys  can  release  glucose  into  the
circulation [7].
In 1950, Drury et al. injected 14C-labeled glucose into rats that had been hepatectomized or
hepatectomized and nephrectomized. His experiment indicated that the kidney represents the
source of the glucose produced endogenously and released into the circulation after hepatec‐
tomy [8].
In other experiments, Teng proved that the renal cortex of the animal models with diabetes
released glucose at a very high rate, but treatment of these animals with insulin could reverse
this effect. A few years later, in 1960, Landau was able to prove, having a similar model, that
gluconeogenesis from pyruvate was increased by the diabetic kidney [6].
In several experiments, Krebs tried to characterize the substrates that the kidney uses for
gluconeogenesis [9], the efficiency of the renal gluconeogenesis in several species [10], and
some aspects of the regulation of renal gluconeogenesis [11]. He could also demonstrate that
the kidney present a greater amount of gluconeogenic enzymes than the liver, and due to the
comparable blood flows (therefore comparable provision of gluconeogenic precursors), Krebs
argued that the kidney might be a gluconeogenic organ in vivo as important as the liver [11].
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2.2. Early human studies
Studies about human renal glucose metabolism started in the late 1950s. They tried to measure
the differences of glucose concentrations between arterial and renal venous blood. By not
taking into consideration that the kidney is able to produce and consume glucose in the same
time, the fact that many researchers found little or no differences between arterial and venous
glucose values led to the conclusion that the kidneys are not able to release glucose [6].
In the mid 1960s, Aber et al. [12] found that kidney can release glucose in patients with
pulmonary disease and the quantity of glucose is negatively correlated with arterial pH
explaining why the greater the acidosis, the greater the renal glucose release. Several years
after, Owen et al. [13] indicated that renal glucose release is increased in very obese patients
who fasted for several weeks. These data led to the current textbook idea that the liver is the
only source of glucose, in general, except after prolonged fasting or under acidosis.
On the other hand, in subjects that undergo liver transplantation, it may still be observed after
removal of the liver, endogenous glucose production [14]. Shortly after the removal of the liver,
the production of endogenous glucose decreased only by 50% (Joseph et al.) [14]. Recent
research using isotopic measurements have indicated that the kidney can release significant
quantities of glucose in postabsorptive normal volunteers.
3. The involvement of kidneys in glucose homeostasis
The plasma glucose concentration is determined by the amount of glucose synthesized, and
the one removed from the circulation and metabolized. This concentration must be maintained
within a relatively narrow range despite the wide daily fluctuations in glucose ingestion and
glucose demands in various tissues [4]. Other substrates such as free fatty acids (FFAs),
glycerol, lactate and ketone bodies have greater daily fluctuations. This can be explained by
the need of the body to protect himself against hyper- and hypoglycaemia. Hyperglycaemia
is associated with both chronic effects (such as nephropathy, retinopathy, neuropathy and
premature atherosclerosis) and also acute complications (including diabetic ketoacidosis and
hyperosmolar hyperglycaemic state that are associated with higher morbidity and mortality).
Hypoglycaemia is also harmful because it can cause neurological events (including coma,
seizures), cardiac arrhythmias and death [4].
The regulation of endogenous production of glucose is determined by hormonal and neural
factors [15]. In the acute phase, glucoregulatory mechanisms involve insulin, glucagon and
catecholamines and they can effect changes in plasma glucose levels in a matter of minutes.
Insulin is able to suppress glucose release in both the kidney and liver by direct enzyme
activation ⁄ deactivation and by reducing the availability of gluconeogenic substrates. Gluca‐
gon has no effect on the kidneys, but it stimulates glycogenolysis and gluconeogenesis in the
liver [16]. Catecholamines also have multiple acute actions. They can stimulate renal glucose
release and glucagon secretion and inhibit insulin secretion [4].
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The kidneys are involved in maintaining glucose homeostasis through three different mech‐
anisms: gluconeogenesis; glucose uptake from the blood for its own energy requests and
reabsorption into the general circulation of glucose from glomerular filtrate in order to
preserve energy [4].
3.1. Renal gluconeogenesis
From the point of view of glucose utilization, the kidney is considered as 2 separate organs;
the renal medulla is characterized mainly by glucose utilization and the renal cortex is
responsible for glucose release. The separation of these activities represents the consequence
of differences in the distribution of numerous enzymes along the nephron. The cells in the
renal medulla can use only glucose for their needs (like the brain) and they have enzymes
capable of glucose-phosphorylation and glycolysis. They can therefore phosphorylate
important amounts of glucose and accumulate glycogen but, because these cells do not have
glucose-6-phosphatase or any other gluconeogenic enzymes, they are unable to release glucose
into the bloodstream. Moreover, the cells in the renal cortex have gluconeogenic enzymes and
they can produce and release glucose into the circulation. However these cells cannot synthe‐
size glycogen because they have little phosphorylating capacity [6].
After a 16-h overnight fast, approximately 10 µmol ⁄ (kg /min) of glucose is released into the
circulation [17]. Almost 50% of this is the result of glycogenolysis from the liver stocks and the
other half is produced by liver and kidney gluconeogenesis. The renal cortex (like the liver)
contains gluconeogenic enzymes and it can synthesize glucose-6-phosphate from precursors
(lactate, glutamine, glycerol and alanine). Because it contains glucose-6-phosphatase, it is able
to release glucose into the blood stream [18] and the human liver and kidneys are the only
organs that can perform gluconeogenesis. Therefore, after an overnight fast, the liver produces
75–80% of glucose released into the circulation and the remaining 20–25% is derived from the
kidneys [4].
Several studies have indicated that human kidneys and liver provide approximately the same
amounts of glucose through gluconeogenesis in postabsorptive period. If the duration of
fasting is increased, the glycogen stores are depleted and gluconeogenesis produces all the
glucose released into circulation.
An important aspect is that kidney and liver use different gluconeogenic precursors and
several hormones have different effects on their release of glucose. Lactate represents the
predominant gluconeogenic precursor in both organs, but regarding the aminoacids, the
kidney prefers to use glutamine, whereas the liver preferentially uses alanine [19]. Insulin can
suppress glucose release in both organs with almost comparable efficacy [20], whereas
glucagon stimulates hepatic glucose release only [21]. Catecholamines normally have a direct
effect only on renal glucose release [22], but their effect on both hepatic and renal glucose
release may be indirect by increasing the quantity of gluconeogenic substrates available and
by suppressing insulin secretion. Other hormones, such as growth hormone, cortisol and
thyroid hormones can stimulate hepatic glucose release over a great period of time [15]. Their
effects on the kidneys regarding glucose release in humans are not completely deciphered.
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In the postprandial state the situation changes significantly. Postprandial glucose levels in the
plasma are determined by insulin and glucagon levels. After glucose ingestion, plasma glucose
levels reach the peak in 60–90 minutes and they return to post-absorptive levels in almost 3–
4 h. The plasma insulin increases four times and the plasma glucagon levels decrease by 50%
[15]. Meyer et al. indicated that endogenous glucose release is reduced by almost 60% and
hepatic glycogenolysis drops to zero in the 4- to 6-h period after meal ingestion [23].This is
happening because this period determines the refilling of hepatic glycogen stores and
inhibition of endogenous glucose release is able to limit postprandial hyperglycaemia. There
is also a reduction in hepatic gluconeogenesis by 82% and glucose molecules generated
through hepatic gluconeogenesis are also directed into hepatic glycogen, not only released in
the circulation.
Renal gluconeogenesis can increase by approximately twofold and it can represent ~60% of
endogenous glucose production in the postprandial state [24]. This mechanism is believed to
facilitate the repletion of glycogen stocks in the liver.
A new concept of hepatorenal glucose reciprocity emerged from the differences observed in
regulation and interchange between renal and hepatic glucose release [24]. This concept refers
to the facts that a pathological or physiological reduction in glucose release by kidney or liver
determines a compensatory increase in glucose release of the other one (liver or kidney) in
order to avoid hypoglycaemia. This situation occurs in the anhepatic phase during liver
transplantation, prolonged fasting, meal ingestion, acidosis and insulin overdoses in diabetes
mellitus [24].
3.2. Glycogenolysis
Glycogenolysis is the breakdown of glycogen to glucose-6-phosphate and a hydrolysis reaction
(using glucose-6-phosphatase) in order to free glucose. The liver is the only organ that contains
glucose-6-phosphatase. So, the cleavage of hepatic glycogen releases glucose, while the
cleavage of glycogen from other sources can release only lactate. Lactate, that is generated via
glycolysis, is often absorbed by other organs and helps regenerating glucose [6].
3.3. Glucose reabsorption
Apart from the important role in gluconeogenesis and the role of renal cortex in glucose uptake,
the kidneys contribute to glucose homeostasis by filtering and reabsorbing glucose. In normal
conditions, the kidneys can reabsorb as much glucose as possible, the result being a virtually
glucose free urine. Approximately 180 grams of glucose are filtered by the glomeruli from
plasma, daily but all of this quantity is reabsorbed through glucose transporters that are
present in cell membranes located in the proximal tubules [24].
These glucose transporters have a limited capacity of reabsorption. If this capacity is exceeded,
glucose usually appears in the urine. The tubular maximum for glucose (TmG), the term used
for the maximum capacity, can vary from 260 to 350 mg/min/1.73 m2 in healthy subjects. It
corresponds to blood glucose levels of 180-200 mg/dL [24]. When the blood glucose is very
high and the TmG is reached, the transporters cannot reabsorb all the glucose and glucosuria
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occurs (Figure 2). Nevertheless, there can be slight differences between the nephrons and the
inaccurate nature of biological systems may potentially lead to the development of glucosuria
when blood glucose is below TmG. Glucosuria may occur at lower plasma glucose levels in
certain conditions of hyperfiltration (eg. pregnancy), but as a consequence of hyperfiltration
and not of significant hyperglycemia [25].
Figure 2. Renal glucose handling. TmG, transport maximum for glucose. Adapted from [26]
In a given day, the kidneys can produce, via gluconeogenesis, 15–55g glucose and it can
metabolize 25–35g glucose. Regarding the glucose metabolic pathways, it is obvious that renal
reabsorption represents the main mechanism by which the kidney is involved in glucose
homeostasis. Therefore, the change in tubular glucose reabsorption may have a considerable
impact on glucose homeostasis [4].
3.3.1. Renal glucose transporters
Glucose is a polar compound with positive and negative charged areas; therefore it is soluble
in water. Its transport into and across cells is dependent on two specialized carrier protein
families: the GLUTs (facilitated glucose transporters) and the SGLTs (sodium-coupled glucose
cotransporters). These transporters are responsible for glucose passage and reabsorption in
several tissue types, including the proximal renal tubule, blood-brain barrier, small intestine
[27]. GLUTs are responsible for the passive transport of glucose across cell membranes, in order
to equilibrate its concentrations across a membrane. SGLTs, on the other hand, are involved
in active transport of glucose against a concentration gradient by means of sodium-glucose
cotransport [27].
There are six members of the SGLT family indicated in Table 1.
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Co-transporter Substrate Tissue distribution
SGLT1 Glucose, galactose Intestine, kidney, heart, trachea, brain, testis,
prostate
SGLT2 Glucose Kidney, brain, liver, muscle, heart
SGLT4 Glucose, mannose Intestine, kidney, uterus, pancreas, liver, brain,
lung, trachea
SGLT5 Unknown Kidney
SGLT6 Glucose, myoinositol Brain, kidney, intestine
SMIT1 Glucose, myoinositol Brain, heart, lung, kidney
Table 1. The sodium glucose co-transporter family (adapted from [27])
SGLT2 is considered the most important because, based on animal studies, it is responsible for
the reabsorption of 90% of the glucose filtered at the glomerulus [24]. The other 10% of glucose
reabsorbed in the proximal tubule is ensured by SGLT1. Of the family of GLUT proteins
expressed in the kidneys, GLUT2 is the major transporter and it releases into circulation the
glucose reabsorbed by SGLTs in the proximal tubular cells [28].
The renal glucose transport was investigated by analyzing the gene mutations within SGLT
family. These can lead to several inherited diseases presenting renal glucosuria that include
familial renal glucosuria (FRG) and glucose-galactose malabsorption (GGM). FRG represents
an autosomal recessive or autosomal dominant disorder caused by several SGLT2 mutations.
Its main characteristic is persistent glucosuria without hyperglycemia or renal tubular
dysfunction. Most of the patients with FRG do not have any clinical manifestations; this is why
FRG is not commonly described as a “disease” but as a condition known as benign glucosuria.
Nevertheless, there is a severe form of FRG, known as type O, where mutations of the SGLT2
gene lead to a complete lack of renal tubular glucose reabsorption. This condition is still
associated with a good prognosis. Due to the fact that FRG is mainly asymptomatic, subjects
with this condition are discovered through routine urinalysis [24].
GGM represents a more serious disease. It is inherited autosomal recessive and is caused by
mutation of the SGLT1 transporter. Its main characteristics are represented by intestinal
symptoms. They appear in the first few days of life and determine glucose and galactose
malabsorption. The consequences are severe; diarrhea and subsequent dehydration may
become fatal unless a special diet (glucose- and galactose-free) is initiated. Some patients with
GGM may present glucosuria but it is typically mild, and some other subjects have no sign of
urinary glucose excretion. This confirms that SGLT1 has a minor role in renal reabsorption of
glucose [24]. The mutations involving the GLUT family are associated with more severe
consequences, because these transporters are more widespread throughout the major organ
systems. SGLT2 and SGLT1 are located mainly in the renal system, but GLUT2 is present
almost everywhere in the organism, having an important role in glucose homeostasis through
its involvement in intestinal glucose uptake, renal reabsorption of glucose, and hepatic uptake
and release of glucose [24].
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Direct in vivo experiments of Vallon et al. on gene targeted mice lacking Sglt2 gene, demon‐
strated that the SGLT2 protein is responsible for all glucose reabsorption in the proximal tubule
and for the bulk of glucose reabsorption in the kidney overall [29]. According to this study, in
wild-type mice, 99.7 ± 0.1% of fractional glucose is reabsorbed and in Sglt2−/− mice (not
expressing SGLT2), only 36 ± 8% is reabsorbed. It was also found that in Sglt2−/− mice, even if
SGLT1 glucose reabsorption is increased (SGLT1 transporters reach their transport maximum),
up regulation of SGLT1 expression does not occur (both SGLT1 mRNA and protein expression
are reduced by ~40%) when the amount of glucose in proximal tubule is increased. The results
of the study of Gorboulev et al. [30] are in correspondence with those of Vallon et al., indicating
that wild-type mice do not use the maximal transport capacity of SGLT1 at normoglycemic
conditions but when glucose load to the SGLT1 is increased (for instance, diabetes and SGLT2
inhibition), SGLT1 may operate at full transport capacity [30].
Molecular structure of SGLTs has been studied thoroughly on SGLT1, which is the first
described member of SGLTs family [31]. SGLT2 is 59% identical to SGLT1 and has almost the
same architecture. Its secondary structure consists of 14-transmembrane helices (TM1–TM13)
with both the NH2 and COOH termini facing the extracellular side of the plasma membrane
[32]. The first kinetic model of Na+/glucose co-transporters was proposed by Parent et al. [33].
4. The kidney in diabetes mellitus
All the metabolic pathways regarding the involvement of the kidney in glucose homeostasis
are modified in subjects with diabetes mellitus. Subjects with type 2 diabetes mellitus (T2DM)
Figure 3. Glucose filtration and reabsorption in the proximal tubule of the kidney (adapted from [28])
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have an increased renal release of glucose into the circulation in the fasting state [34]. Although
one can think that the liver determines increased glucose release into the circulation in diabetes,
the liver and the kidneys have comparable increase in renal glucose release (2.60 and 2.21
µmol ⁄ (kg min). The kidney can increase its glucose production with 300% compared with the
liver that can increase gluconeogenesis only by 30%. Gluconeogenesis, in the kidney, could
explain this glucose increase, in the fasting state [34].
In postprandial state, renal glucose release is greater increased in subjects with T2DM than in
people without glucose metabolism abnormalities [35]. Meyer et al. studied systemic glucose
appearance in subjects with T2DM and individuals with normal glucose tolerance over several
hours following ingestion of 75 g glucose. They found that it was significantly greater in
diabetic patients than in normal subjects (100.0 ± 6.3 vs. 70.0 ± 3.3 g; p < 0.001). The result was
determined by a higher endogenous glucose release because the general appearance of
ingested glucose was only 7 g greater in the subjects with DM. Almost 40% of the increased
endogenous glucose release was caused by increased renal glucose release [35]. This fact was
determined mainly by impaired suppression of endogenous glucose release and secondary by
reduced initial splanchnic sequestration of ingested glucose. This effect is expected in diabetic
patients that have decreased postprandial insulin release and insulin resistance, taking into
account that renal glucose release is regulated by insulin [4].
Both renal glucose uptake and glucose production are increased in both the postprandial and
post-absorptive states in diabetic patients [35].
It is well known that glucosuria in diabetic patients occurs at different plasma glucose levels
compared with the levels where glucosuria can occur in non-diabetic individuals [36]. This is
determined by the increased glucose reabsorbtion in subjects with diabetes mellitus. Therefore,
the Tm for glucose is increased and glucosuria may occur at higher than normal blood glucose
levels. Several studies indicated that the Tm increased from near 350 mg ⁄ min in subjects with
normal glucose tolerance to approximately 420 mg⁄min in subjects with diabetes mellitus [36].
As an evolutionary process, the kidney was able to develop a system in order to reabsorb all
of the filtered glucose in order to conserve energy especially at a time when energy intake was
reduced. Therefore, this may be considered as an adaptive response as the SGLT2 transport
increases in response to hyperglycaemia. But, in subjects with diabetes this adaptive response
is considered maladaptive, and glycosuria occurs only at very high plasma glucose levels.
Thus, instead of allowing the kidneys to excrete excess of glucose, SGLT2 transporters help
maintain a higher plasma glucose concentrations [1].
Human and animal studies of renal cells have demonstrated enhanced expression of SGLT2
transporters [37]. Factors like hyperglycaemia, albumin and angiotensin II have been reported
to increase the expression of SGLT2 in T2DM [37].
It has also been demonstrated that acidosis increases renal gluconeogenesis and impairs
hepatic gluconeogenesis [38]. Therefore one can speculate that the kidney represents an
important factor that accelerates gluconeogenesis in diabetic ketoacidosis. Moreover, the
exaggerated increase in renal glucose release can be the result of the insufficient suppression
of endogenous glucose release postprandial in diabetic patients [39]. These processes can
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explain the quantity of glycogen stored in diabetic kidneys. A major part of the high renal
glucose release found in subjects with diabetes may be determined by increased renal glyco‐
genolysis [6].
5. Diabetic nephropathy
Diabetes represents the most common single cause of end-stage renal disease (ESRD) in the
United States and Europe. There can be several factors responsible for this, including an
increased prevalence of T2DM, longer life spans among patients with diabetes, and better
recognition of kidney disease [40]. Comparing with subjects with type 1 diabetes mellitus, only
a smaller fraction of those with T2DM develop ESRD, but due to the increased prevalence of
T2DM, these individuals represent more than a half of those with diabetes on dialysis. There
are numerous variables in progressing to nephropathy, including racial/ethnic variability
because Native Americans, Hispanics and African Americans are at much greater risk of
developing ESRD than non-Hispanic white subjects with T2DM [40].
The first clinical signs of nephropathy are represented by low, but abnormal, levels (≥30
mg/day or 20µg/min) of albumin in the urine (previously referred to as microalbuminuria).
The detection of albumin in the urine increases the risk of progression to persistent albumi‐
nuria, progressive decline in glomerular filtration rate (GFR), increased blood pressure and
cardiovascular morbid-mortality. But because T2DM may be present for many years before
diagnosis, a higher proportion of individuals with T2DM have microalbuminuria and overt
nephropathy shortly after diagnosis. It is known that without treatment, 20-40% of patients
with T2DM and microalbuminuria progress to overt nephropathy. Nevertheless, after 20 years
from the onset of nephropathy, only 20% will have progressed to ESRD [40]. The explanation
comes from the greater risk among subjects with diabetes and chronic kidney disease of dying
from cardiovascular disease than progressing to ESRD.
Several clinical trials indicate that the onset and development of diabetic nephropathy may be
significantly influenced by numerous interventions including tight glucose control and also
use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. This is the
reason why annual screening for microalbuminuria is critical since it can lead to early diagnosis
of nephropathy. Numerous studies, including the well-known Diabetes Control and Compli‐
cations Trial and United Kingdom Prospective Diabetes Study indicated that intensive
glycemic control represent a very important step in reducing the risk of developing microal‐
buminuria and overt nephropathy [40].
New data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) trial offers hope regarding the benefic effects of tight
glucose control on decreasing the risk of nephropathy [41]. In the ADVANCE trial, after almost
5 years, subjects that were on intensive glycemic control had a 10% relative reduction in the
combined outcome of major macrovascular and microvascular events. This was happening
mainly because of a 21% relative reduction in the risk of developing nephropathy. The
intensive glucose control is also important because it is associated with a 9% reduction in new
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onset microalbuminuria [41]. Results of this study are of great importance since renal impair‐
ment is strongly associated with future risk of major vascular events, and death in patients
with diabetes. Nevertheless, the role of modified renal glucose reabsorption in the progression
of diabetic nephropathy is not elucidated [4].
6. Therapeutic implications
6.1. SGLT2 inhibitors
SGLT2 is highly specific for (several authors consider that it is found only in) the proximal
tubules of the kidney, as compared to SGLT1 or GLUT2, therefore it is a preferred target for
more specific renal pharmacologic interventions. Thus, the idea of interfering with the activity
of the SGLT2 has gained much attention [2].
Inhibition of SGLT2 transporter ‘resets’ the reabsorption system by lowering the threshold for
glycosuria, resulting the correction of the hyperglycemia [1]. Reduction of the blood glucose
level can improve insulin resistance in muscle by increasing insulin signaling, GLUT4 and
glycogen synthase activity [1].
The history of SGLT2 inhibitors starts in 1835 when phlorizin was found in the root bark of
apple tree [42]. Many years after, it was found to be a non-specific SGLT1 and SGLT2 and it
could increase glucosuria and reduce blood glucose levels and normalize insulin sensitivity
in a pancreatectomized animal model of T2DM [43]. Nevertheless, it could not become a
treatment for diabetes due to numerous side effects. Being non-selective and inhibiting SLGT1
at the intestinal brush border, it can cause serious problems regarding the absorption of dietary
glucose. Inhibition of SGLT1 can result in glucose–galactose malabsorption and cause diarrhea,
events that occur naturally in SGLT1 deficiency [44]. Moreover, in the intestine, phlorizin is
poorly absorbed and is rapidly hydrolyzed to phloretin, a substance that blocks GLUT1,
leading to disturbance in glucose uptake in several tissues [45]. Highly-specific inhibitors of
SGLT2 have subsequently been developed in order to overcome some of these shortcomings.
Ellsworth et al [46] discovered a group of C-aryl glycosides that includes dapagliflozin [47]
and canagliflozin [48]. They are resistant to degradation produced by β-glucosidase enzymes
in the gastrointestinal tract. Moreover, dapagliflozin has a very high sensitivity for SGLT2
compared to SGLT1, blocking renal glucose reabsorption by almost 40–50%. Using this
treatment, they can be excreted up to 80–85 g of glucose per day [47]. Clinical trials evaluating
the treatment with dapagliflozin, either as monotherapy or in association with metformin or
with insulin in subjects with T2DM have demonstrated its efficacy in reducing glucose and
HbA1c levels [3]. Pharmacokinetics and bioavailability of dapagliflozin are not influenced by
a high-fat meal and there are no reports regarding any interactions with several other drugs
used in the treatment of T2DM [3].
Human trials analyzing canagliflozin are more limited than for dapagliflozin. It has been
indicated that both drugs have similar therapeutic characteristics [3]. Canagliflozin could
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induce an important, dose-dependent decrease in the mean renal glucose threshold to
approximately 60 mg/dl (3.33 mmol/l) [49].
There are numerous other SGLT2 inhibitors including sergliflozin, remogliflozin, ipraglifozin
and empagliflozin. Some of them, such as ipraglifozin and empagliflozin, are being tested in
phase III trials and are promising very good results while other compounds have disappointed
in clinical trials due to possible side effects (sergliflozin) or to susceptibility to hydrolysis by
β-glucosidase enzymes (sergliflozin and remogliflozin) [3].
As  already mentioned,  patients  diagnosed with  FRG often  gave  higher  urinary  glucose
excretion of almost 120 g per day. It remains unclear why treatment with SGLT2 inhibi‐
tors cannot achieve the same levels of glycosuria even when the maximal doses are used.
Moreover, SGLT2-null mice can only reabsorb up to a third of the filtered glucose [29], but
subjects taking dapagliflozin reabsorb ~50% at the highest doses. Moreover, the nonselec‐
tive inhibitor phlorizin completely blocks reabsorption. One possible explanation may be
that SGLT1 has a greater role in the kidney than it was previously imagined [50]. There
are some theories that include antisense nucleotide technology to knock out SGLT2 in order
to  achieve  a  higher  degree  of  blockade  of  glucose  reabsorption  than  SGLT2  inhibition.
Preliminary  data  in  human subjects  with  T2DM with  moderate  or  severe  renal  impair‐
ment  indicate  that  SGLT2  inhibition  determines  proportionally  less  glycosuria  than  in
subjects  with  preserved  renal  function  [51].  These  findings  confirm  that  a  low  GFR  in
subjects with T2DM is accompanied by a comparable loss of tubular absorptive capacity
that represents the anticipated consequence of nephron loss [3].
The approach of lowering hyperglycaemia in T2DM by blocking glucose reabsorption has
many attractions. One of them is represented by the activity of SGLT2 inhibitors that is not
dependent on pancreatic β-cell function, which deteriorates over time. This is the only class of
drugs that present this mechanism of action. Other drugs such as the insulin secretagogues
[glinides, sulphonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like
peptide 1 (GLP-1) agonists] and insulin sensitizers (thiazolidinediones and metformin) depend
on insulin secretion. The insulin independence of their action indicates that the risk of
hypoglycaemia is very low [6].
As a consequence, the liver can react to the induced glycosuria by increasing glucose release.
The mechanism for increased liver glucose excretion is not well understood. The relative small
decrease in plasma glucose but also insulin concentrations after massive glycosuria may
stimulate endogenous glucose release. Other additional mechanisms are not excluded.
Moreover, glucose output is usually not decreased enough to attain and maintain normal
glucose values in patients with T2DM treated with SGLT2 inhibitors [52]. Adaptation of
glucose metabolism to massive glycosuria needs further investigation.
Osmotic diuresis accompanies glycosuria. It is usually detected an increase in urine output
with acute SGLT2 inhibition; while chronic administration of SGLT2 inhibitors is accompanied
by an excess urine volume of 200–600 ml per day. As a consequence, haematocrit increases are
noted but they are moderate and clinical signs of volume depletion, such as tachycardia and
orthostatic hypotension, are rarely met [52].
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SGLT2 inhibitors determine glucose and sodium reabsorption blocking and natriuresis also
occurs. Changes in serum sodium concentration are not frequent with chronic SGLT2 inhibi‐
tion because at the nephron level, reduced sodium reabsorption in the proximal segment
determines the increase of sodium delivery to the juxtaglomerular apparatus, and the inhibi‐
tion of the renin-angiotensin-aldosterone system (RAAS) occurs. In experimental diabetic rats
fed a high-salt diet [53], SGLT2 inhibition could prevent blood pressure increase. This effect
may be countered by an activation of the RAAS if volume depletion appears as a consequence
of excessive diuresis. SGLT2 inhibition in patients with T2DM also determines the reduction
of blood pressure levels (by 2–5 mmHg) [52]. The possible explanations may be the enhanced
natriuresis and RAAS deactivation [3]. Because most of the individuals with T2DM also present
high blood pressure, this effect is of great importance in clinical practice.
Several phase III clinical trials of dapagliflozin reported the decrease of serum uric acid
concentrations [54]. Sodium and urate are handled together in several physiological circum‐
stances, and also in response to several drugs such as diuretics and antihypertensives. Several
sodium-dependent phosphate transporters may also excrete urate into the urine. Therefore,
the excretion of urate determined by SGLT2 inhibitors is explained by this mechanism. GLUT9
might represent an alternate explanation. GLUT9 represents an antiporter that exchanges
glucose for uric acid; his two isoforms act together to reabsorb glucose from the tubule lumen
in exchange for uric acid [55].
Another important effect of SGLT2 inhibition is weight loss. Clinical trials in patients with
T2DM have reported a decrease of 2.5–4.0% of body weight [52]. At first, this weight loss is
predominantly due to fluid depletion, but soon after that appears the loss of subcutaneous and
visceral depots of adipose tissue. This effect is caused by an important caloric loss through the
urine. Nevertheless, body weight loss remains constant after several months of treatment [3].
Clinically, the most frequent and undesired effect of SGLT2 inhibitors is represented by high
incidence of genitourinary infections. These infections were observed more frequent in women
than in men taking SGLT2 inhibitors and tend to occur in susceptible subjects; these include
postmenopausal women, history of urinary tract infections or poor hygiene. Interestingly,
studies with dapagliflozin in addition to metformin reported a not significant difference in
incidence of genitourinary infections between individuals in the placebo and treatment groups
[56], while in subjects receiving dapagliflozin in addition to insulin, the difference was
significant [57]. This might explain a possibly increased risk of this adverse effect in patients
with advanced T2DM (when immune function may be defective) [3].
The incidence of genitourinary infections tends to decrease in time, with long-term treatment,
when the adaptation to the treatment is installed or exclusion of susceptible individuals over
time appears. More important, infections of the upper urinary tract, that tend to be more severe
than those of the lower urinary tract, are not frequent, although the reported patient exposure
is presently too limited to rule out this adverse event [56].
Another reported event was a very small, but consistent, increase in PTH levels (<2.0 ng/l)
together with increased plasma phosphate concentration. The increased PTH might indicate
a mild form of secondary hyperparathyroidism but the available studies so far offer very few
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data regarding the long-term effects of SGLT2 inhibitors on bone metabolism, making room
for other clinical studies on this important issue.
There have been reports regarding several cases of bladder cancer and breast cancer, in subjects
with T2DM receiving treatment with dapagliflozin [58]. Trials with large numbers of patients
with different SGLT2 inhibitors are required to assess any associated increased risks of breast
or bladder cancer [3].
Theoretical safety and tolerability concerns also include impairment in renal function [54].
Although, until now, there are no data indicating that the SLGT2 inhibitors would determine
or be responsible for deterioration of renal function, the few clinical studies investigating these
drugs have relatively short duration (6-12 months). Moreover, several authors are speculating
that SGLT2 inhibitors may play an important role in preventing diabetic nephropathy. First,
improved glycaemic control decreases the risk of diabetic nephropathy and other diabetic
complications [40]. Second, by increasing the quantity of sodium in the juxtaglomerular
apparatus, the use of SGLT2 inhibitors may determine a protective effect on the kidney,
independently of glucose decreased.
In T2DM, the high quantity of glucose and sodium absorbed in the proximal tubule reduces
the quantity of sodium to be delivered to the juxtaglomerular apparatus. Thus, the glomerulo-
tubular feedback reflex is activated; this leads to high renal plasma flow, increased intra-
glomerular pressure and elevated GFR. All these processes can induce normal salt delivery to
the juxtaglomerular apparatus; however this can result in increased intra-glomerular pressure.
All these alterations in renal hemodynamic lead to renal hypertrophy and eventually the result
is represented by diabetic nephropathy [59]. SGLT2 inhibitors may prevent diabetic nephrop‐
athy by inhibiting the glomerulo-tubular feedback reflex and, therefore increasing sodium
delivery to the distal nephron [1]. Nevertheless, this therapy is contraindicated in patients with
estimated GFR (eGFR) <45 mL/min/1.73 m2 and must be used at lower doses at eGFRs of 45-60
mL/min/1.73 m2 [60]. New clinical trials are expected to evaluate the efficacy and safety of
SGLT2 inhibitors.
The pathogenesis of type 2 diabetes combines numerous defects in many tissues. Therefore,
there is no single antidiabetic drug that can compensate all the metabolic disturbances, and a
good treatment for diabetes will require the use of multiple drugs in combination. Having a
unique pharmacokinetic and a special mechanism of action, the SGLT2 inhibitors can be used
not only as monotherapy [61] but also in combination with currently available antidiabetic
agents [62,63].
7. Conclusions
Although not traditionally discussed, the kidneys play a very important role in maintaining
glucose homeostasis by gluconeogenesis and glucose reabsorption, the latter being mediated
by active (SGLT) and passive (GLUT) transporters. Only recently, excessive renal glucose
reabsorption was taken into consideration regarding its importance in the physiopathology of
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T2DM. In hyperglycemia, the kidneys may play an exacerbating role by reabsorbing excess
glucose, bringing their contribution to chronic hyperglycemia. Knowing the kidneys’ role in
glucose homeostasis and the effect of glucose dysregulation on the kidneys is very important
for the optimal management of T2DM and prevention of associated renal complications. The
numerous metabolic defects found in T2DM imply the use of several therapies. SGLT2
inhibitors represent a new promising class of drugs for the treatment of T2DM.
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